Researchers at Retro Biosciences, a longevity startup backed by OpenAI CEO Sam Altman, have begun human clinical trials aimed at addressing Alzheimer’s disease. This milestone comes as the company secures $1.8 billion in funding, signaling a shift in the biotech industry toward treating aging proactively rather than reactively. Retro’s mission is to add 10 healthy years to our lives, focusing not just on longevity but on improving quality of life by reducing the risk of chronic diseases and cognitive decline.

For those interested in aging well, this development could lead to significant benefits. The trial is centered on an oral drug designed to enhance the body’s natural cleanup system, known as autophagy, which removes toxic protein buildup in cells. If successful, this could help maintain cognitive function and overall health as we age. The initial phase of the study is primarily assessing safety, but it also aims to measure biological markers that indicate the drug’s effectiveness.

Currently, the research is in its early stages, with the first human trial taking place in Australia. While the results are not yet definitive, the early feedback from the trial has been positive, with no major safety concerns reported so far. The company plans to share initial data by August 2026. However, the longevity field has seen its share of setbacks, and many promising therapies have struggled in human trials. Retro’s cautious approach, balancing ambitious goals with achievable clinical milestones, may provide a more realistic pathway toward meaningful advancements in aging research.

As the industry evolves, it’s essential to stay informed about developments like this, which could ultimately lead to practical solutions for healthier aging.

Source: longevity.technology